VIMAB Group AB (publ) OMXSTO:VIMAB:
Q3 NET SALES SEK 93 MILLION
Q3 EBIT LOSS SEK 3.7 MILLION VERSUS LOSS SEK 9.9 MILLION YEAR AGO
Vimab Q3 Net Sales SEK 93 Million
Earlier from VIMAB
- VIMAB: Revenue fell 17.5% in Q2, but major post-period deals are set to boost H2 results
- VIMAB: Revenue and profit declined, but large battery orders and new financing support future prospects
- VIMAB: Major loss in 2024, but large battery orders and divestment set stage for 2025 turnaround
- VIMAB: Q3 loss amid revenue drop, but record battery order and strategic shift signal future growth
- VIMAB: Sales growth strong but profitability pressured by investments; Q3 profit expected
Later from VIMAB
- Aerix Replaces Grimaldi As Acquirer Of Vimab AB
- Vimab Group Resolves On Rights Issue Of SEK 127.4 Mln
- Sagri Development, Aerix Industri Cancel Deal On Acquisition Of Vimab Ab
- Vimab Group Announces Preliminary Outcome Of Rights Issue
- Vimab Group Q4 Net Sales SEK 86.6 Mln
Follow VIMAB into a list and get an email when it puts out news.
Follow VIMAB